Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Multi-Parametric MRI and PET Imaging Improve Accuracy of Prostate Cancer Biopsies

By MedImaging International staff writers
Posted on 25 Jul 2016
Researchers have demonstrated that a combination of PET and multi-parametric MR imaging can improve targeted prostate cancer biopsies.

The study was published in the July 2016 issue of The Journal of Nuclear Medicine and found that adding F-18-choline Positron Emission Tomography (PET) molecular imaging to multi-parametric Magnetic Resonance Imaging (mpMRI) improves the chance of recognizing significant prostate cancer during targeted trans-rectal prostate biopsies.

The study, part of an ongoing prospective clinical trial was carried out by researchers at the University of Michigan (UMS; Ann Arbor, MI, USA) and included 36 subjects of which 15 were eventually identified with significant prostate cancer. More...
The researchers concluded that image registration using fusion PET imaging together with MRI real-time Trans-Rectal Ultrasound (TRUS) during targeted prostate biopsies was accurate and clinically feasible. The addition of F-18-choline PET, to the mpMRI procedure resulted in improved identification of significant prostate cancer.

Morand Piert, MD, radiology professor, Division of Nuclear Medicine, University of Michigan, said, "Our positive results suggest that in the future, PET/MRI may become a one-stop imaging test for men with suspected but undetected prostate cancer or for patients undergoing surveillance for known low-risk prostate cancer. Since prostate cancer is often multi-focal and presents with multiple lesions of varying risk, it is important to identify the lesions that harbor the greatest malignant potential. Accurate identification of clinically significant cancer and avoidance of clinically insignificant cancer is the centerpiece of modern prostate cancer diagnosis. The use of advanced imaging to inform placement of biopsy needles promises to greatly minimize the uncertainty associated with prostate cancer care."

Related Links:
University of Michigan



Post-Processing Imaging System
DynaCAD Prostate
MRI System
nanoScan MRI 3T/7T
Computed Tomography System
Aquilion ONE / INSIGHT Edition
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to MedImaging.net and get access to news and events that shape the world of Radiology.
  • Free digital version edition of Medical Imaging International sent by email on regular basis
  • Free print version of Medical Imaging International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of Medical Imaging International in digital format
  • Free Medical Imaging International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

General/Advanced Imaging

view channel
Image: Concept of the photo-thermoresponsive SCNPs (J F Thümmler et al., Commun Chem (2025). DOI: 10.1038/s42004-025-01518-x)

New Ultrasmall, Light-Sensitive Nanoparticles Could Serve as Contrast Agents

Medical imaging technologies face ongoing challenges in capturing accurate, detailed views of internal processes, especially in conditions like cancer, where tracking disease development and treatment... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.